What is Onivyde?
Onivyde (nal-IRI) is a liposomal formulation of irinotecan, a topoisomerase I inhibitor used in cancer treatment [1]. It is administered intravenously [1].
What is Onivyde approved for?
Onivyde is approved for use in combination with fluorouracil and leucovorin in adult patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy [1].
What is the mechanism of action for Onivyde?
Onivyde works by inhibiting topoisomerase I, an enzyme essential for DNA replication and repair, thus leading to DNA damage and cancer cell death [1]. The liposomal formulation is designed to alter the pharmacokinetic profile of irinotecan, potentially improving its delivery to tumor sites and reducing systemic toxicity [1].
When did Onivyde receive FDA approval?
Onivyde received FDA approval for its indication in metastatic pancreatic cancer on October 24, 2015 [1].
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis (mouth sores), and abdominal pain [1]. Serious side effects can include severe diarrhea, neutropenia (low white blood cell count), and febrile neutropenia [1].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals, Inc. [1].
Are there any patent or exclusivity considerations for Onivyde?
Information regarding specific patents and exclusivity for Onivyde can be found on resources like DrugPatentWatch.com, which tracks patent expirations and other intellectual property data for pharmaceuticals [2]. These details are crucial for understanding when generic or biosimilar versions might become available.
What are the treatment outcomes with Onivyde?
Clinical trials have demonstrated an improvement in overall survival for patients treated with Onivyde in combination with fluorouracil and leucovorin compared to those treated with fluorouracil and leucovorin alone, in the second-line setting for metastatic pancreatic cancer [1].
What are the risks associated with Onivyde treatment?
The primary risks associated with Onivyde treatment are related to its toxicities, particularly severe diarrhea and myelosuppression (bone marrow suppression), which can lead to increased susceptibility to infections [1]. Close monitoring of patients for these adverse events is essential during treatment [1].
What are other treatment options for metastatic pancreatic cancer?
Other treatment options for metastatic pancreatic cancer depend on the stage of the disease, prior treatments, and the patient's overall health. These can include other chemotherapy regimens, targeted therapies, immunotherapy (though its role is still evolving), and palliative care to manage symptoms [3].
How is Onivyde administered?
Onivyde is administered as an intravenous infusion, typically over a period of 90 minutes [1].
---
Sources:
1. https://www.fda.gov/drugs/drug-approvals/onivyde-nal-iri
2. https://drugpatentwatch.com/
3. https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq